Sinusitis News and Research

Latest Sinusitis News and Research

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluoroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

2 Sep 2009

OHSU study reveals that fluoroquinolones may cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

1 Sep 2009

Smell and taste disorders can be treated

When flowers aren’t fragrant and spicy foods don’t zing, the senses may be impaired. But don’t assume that diminished senses of taste and smell are due to aging, says the August issue of Mayo Clinic Women’s HealthSource.

13 Aug 2009

Widespread general use of fluoroquinolones is creating drug-resistant tuberculosis

Use of a common antibiotic may be undercutting its utility as a first-line defense against drug-resistant tuberculosis (TB). Fluoroquinolones are the most commonly prescribed class of antibiotics in the U.S. and are used to fight a number of different infections such as sinusitis and pneumonia. They are also an effective first line of defense against TB infections that show drug resistance. New research shows, however, that widespread general use of fluoroquinolones may be creating a strain of fluoroquinolone-resistant TB.

11 Aug 2009

GlaxoSmithKline opens pneumonia vaccine plant In Singapore

Drug maker GlaxoSmithKline (GSK) on Tuesday opened a $600 million plant in Singapore that is slated to begin producing vaccines to fight pneumonia-causing bacteria in 2011, Reuters reports.

10 Jun 2009

Sleep disordered breathing in children in a general population sample: prevalence and risk factors

A study in the June 1 issue of the journal SLEEP found that waist circumference and body mass index (BMI) are consistent, independent risk factors for all severity levels of sleep disordered breathing (SDB) in children, suggesting that as with adult SDB, metabolic factors are important risk factors for childhood SDB.

1 Jun 2009

Budesonide nasal wash shows promise for chronic rhinosinusitis

A nasal wash containing the corticosteroid budesonide appears to reduce symptoms of chronic rhinosinusitis without suppressing the function of the adrenal glands, a known complication of this type of drug that would indicate absorption throughout the whole body, according to a report in the March issue of Archives of Otolaryngology-Head & Neck Surgery.

16 Mar 2009

FDA grants priority review of Cinryze C1 inhibitor as treatment for acute attacks of hereditary angioedema

ViroPharma Incorporated has announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of Hereditary Angioedema (HAE).

5 Feb 2009

New mouse model for peanut allergy

Chicago researchers report the development of a new mouse model for food allergy that mimics symptoms generated during a human allergic reaction to peanuts.

12 Jan 2009

AstraZeneca responds to FDA advisory committees' recommendation on SYMBICORT

On December 11, 2008, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) - including the Drug Safety & Risk Management Advisory Committee, the Pediatric Advisory Committee, and the Pulmonary-Allergy Drugs Advisory Committee - completed a review of the benefits and risks of asthma medications containing long-acting beta-agonists (LABAs).

12 Dec 2008

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

ViroPharma Inc. has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema (HAE).

1 Dec 2008

If cold symptoms persist it could be sinusitis

If your stuffy nose and headache last for more than two weeks, it may be more serious than a cold.

1 Dec 2008

Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid

Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.

10 Nov 2008

Science backs old fashioned belief in the healing powers of honey

Research by Canadian scientists lends support to the old fashioned belief in the healing powers of honey.

25 Sep 2008

Scientists engineer first drug-delivery particles capable of passing through human mucus

Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus - regarded by many as nearly impenetrable - and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society.

20 Aug 2008

AstraZeneca submits sNDA for SYMBICORT in chronic obstructive pulmonary disease

AstraZeneca today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.

30 Apr 2008

Study explains why steroid therapy for sinusitis and asthma loses its punch over time

Scientists at Johns Hopkins have outlined a new path for potential therapies to combat inflammation associated with sinusitis and asthma based on a new understanding of the body's earliest immune response in the nose and sinus cavities.

29 Apr 2008

Doctors should consider alternatives to antibiotics for sinusitis

When suffering through a sinus infection, many people ask for an antibiotic to speed their recovery. However, a recent review of clinical trials found that while antibiotics can provide minor improvements in uncomplicated sinusitis cases, most patients recover without the drugs within two weeks.

24 Apr 2008

Antibiotics for acute maxillary sinusitis

A Cochrane Systematic Review of medical research found that four out of five patients who are seen in primary care with simple sinusitis improved within two weeks even if they had not been given antibiotics.

17 Apr 2008

Alcon's PATANASE nasal spray approved by FDA for treatment of nasal allergy symptoms

Alcon, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved PATANASE(R) (olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.

16 Apr 2008

Sinusitis News and Research

Latest Sinusitis News and Research

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

OHSU study reveals that fluoroquinolones may cause double vision

Smell and taste disorders can be treated

Widespread general use of fluoroquinolones is creating drug-resistant tuberculosis

GlaxoSmithKline opens pneumonia vaccine plant In Singapore

Sleep disordered breathing in children in a general population sample: prevalence and risk factors

Budesonide nasal wash shows promise for chronic rhinosinusitis

FDA grants priority review of Cinryze C1 inhibitor as treatment for acute attacks of hereditary angioedema

New mouse model for peanut allergy

AstraZeneca responds to FDA advisory committees' recommendation on SYMBICORT

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

If cold symptoms persist it could be sinusitis

Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid

Science backs old fashioned belief in the healing powers of honey

Scientists engineer first drug-delivery particles capable of passing through human mucus

AstraZeneca submits sNDA for SYMBICORT in chronic obstructive pulmonary disease

Study explains why steroid therapy for sinusitis and asthma loses its punch over time

Doctors should consider alternatives to antibiotics for sinusitis

Antibiotics for acute maxillary sinusitis

Alcon's PATANASE nasal spray approved by FDA for treatment of nasal allergy symptoms

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Sinusitis News and Research

Latest Sinusitis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in